Home Innovation That Matters

Innovation That Matters

Inside Perspectives on Gene Editing: An Interview with Agenovir CEO Dirk Thye

Using its deep virology expertise and targeted genome editing technologies, Agenovir is on a mission to develop novel antiviral therapeutics, bringing hope to millions of patients who suffer from devastating, persistent viral infections. In particular, the South San Francisco start-up is using CRISPR-Cas9 technology to create topical...

Inside Perspectives on Gene Editing: An Interview with MPM Capital’s Mitchell Finer

MPM Capital Managing Director Mitchell H. Finer, Ph.D. – a 30-year gene and cell therapy veteran – describes the relatively new science of gene editing, or genome engineering, as “very exciting.” But he also is quick to add that genome engineering as a marketed...

Inside Perspectives on Gene Editing: An Interview with Cellectis CEO André Choulika

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). Based in New York City and Paris, the company is capitalizing on its 17 years of expertise in gene editing. Built on its flagship...

Inside Perspectives on Gene Editing: An interview with Sangamo CEO Sandy Macrae

Sangamo Therapeutics is a leader in translating ground-breaking science into genomic therapies that can have a major impact on patients who are suffering from genetic diseases. Sangamo has developed strong capabilities in gene therapy and editing to produce therapeutics proteins to generate new types...

Idea Factory: From the Classroom to the Lab, Robert Langer’s Impact is Felt Around the Globe

By Rich Soll, Senior Vice President, Research Service Division, WuXi AppTec (@richsollwx) Known as the “Thomas Edison of Biomedicine," professor Robert Langer is one of the most highly cited individuals in history, and founder of more than 40 biotech companies. While he is widely regarded...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide

We are pleased to announce that WuXi has acquired ResearchPoint Global (RPG), a U..S-based contract research organization (CRO) with expertise spanning across all major...